Physician critiques new Alzheimer's drug approval

01 ottobre 2025 Riportato dall'IA

In an opinion piece published on MedPage Today, oncologist Vinay Prasad argues that the FDA's approval of lecanemab for Alzheimer's disease is premature and overlooks significant risks. He calls for more rigorous evidence before widespread use.